- Home
- MX vs CUE Comparison
MX vs CUE Comparison
Compare MX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MX | CUE |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 124.5M |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MX | CUE |
|---|---|---|
| Price | $3.72 | $26.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 1.0M | 162.7K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.06 | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $178,860,000.00 | $27,466,000.00 |
| Revenue This Year | $8.55 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $2.18 | $0.17 |
| 52 Week High | $9.86 | $45.50 |
Technical Indicators
Market Signals| Indicator | MX | CUE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.